Latest survey findings indicate significant decline in molecular testing for cancer during COVID-19 pandemic

Microneedle patches for microdosing psychedelic pharmaceuticals
23 February 2021
Distinguishing between two very similar pediatric brain conditions
23 February 2021

Latest survey findings indicate significant decline in molecular testing for cancer during COVID-19 pandemic

The Association for Molecular Pathology (AMP), the premier global, molecular diagnostic professional society, today released the preliminary results of its “Molecular Testing for Cancer during COVID-19” survey of clinical laboratories. AMP’s ongoing series of COVID-19 surveys are administered to monitor, understand, and collect real-time data on laboratories’ efforts and experiences during the COVID-19 pandemic response. The latest anonymous survey assessed how important components of molecular diagnostic testing for cancer, including testing volumes, laboratory operations, clinical trial testing, patient samples, and turnaround times, were affected by the COVID-19 pandemic. The preliminary results included feedback from 163 representatives from academic medical centers, commercial reference laboratories, and community hospitals in the US and around the world.

Comments are closed.